Overview

Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma

Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study the safety and efficacy of Camrelizumab treating patients with newly diagnosed glioblastomas.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Temozolomide